Cargando…

Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART

BACKGROUND: Treatment options are limited for TB/HIV-coinfected children who require PI-based ART. Rifabutin is the preferred rifamycin for adults on PIs, but the one study evaluating rifabutin with PIs among children was stopped early due to severe neutropenia. METHODS: We evaluated rifabutin safet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rawizza, Holly E, Oladokun, Regina, Ejeliogu, Emeka, Oguche, Stephen, Ogunbosi, Babatunde O, Agbaji, Oche, Odaibo, Georgina, Imade, Godwin, Olaleye, David, Wiesner, Lubbe, Darin, Kristin M, Okonkwo, Prosper, Kanki, Phyllis J, Scarsi, Kimberly K, McIlleron, Helen M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879135/ https://www.ncbi.nlm.nih.gov/pubmed/33294914 http://dx.doi.org/10.1093/jac/dkaa512

Ejemplares similares

Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir
por: Moultrie, Harry, et al.
Publicado: (2015)

Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy
por: Naiker, Suhashni, et al.
Publicado: (2014)

Longitudinal evaluation of adherence, retention, and transition patterns of adolescents living with HIV in Nigeria
por: Meloni, Seema T., et al.
Publicado: (2020)

Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment
por: Shiau, Stephanie, et al.
Publicado: (2014)

Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
por: Zhang, C, et al.
Publicado: (2010)

The Safety, Effectiveness and Concentrations of Adjusted Lopinavir/Ritonavir in HIV-Infected Adults on Rifampicin-Based Antitubercular Therapy
por: Decloedt, Eric H., et al.
Publicado: (2012)

Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV
por: Chabala, Chishala, et al.
Publicado: (2023)

Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir
por: Rabie, Helena, et al.
Publicado: (2020)

Randomised Pharmacokinetic Trial of Rifabutin with Lopinavir/Ritonavir-Antiretroviral Therapy in Patients with HIV-Associated Tuberculosis in Vietnam
por: Lan, Nguyen Thi Ngoc, et al.
Publicado: (2014)

Safety and Tolerability of High Dose Atazanavir–Ritonavir and Lopinavir–Ritonavir in Pregnant Women Living with Human Immunodeficiency Virus
por: McLaughlin, Milena M, et al.
Publicado: (2017)

Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients
por: Kouanda, Seni, et al.
Publicado: (2020)

Implication of First-Line Antiretroviral Therapy Choice on Second-Line Options
por: Meloni, Seema T, et al.
Publicado: (2017)

Drug resistance patterns following pharmacy stock shortage in Nigerian Antiretroviral Treatment Program
por: Meloni, Seema T., et al.
Publicado: (2017)

The role of point-of-care viral load monitoring in achieving the target of 90% suppression in HIV-infected patients in Nigeria: study protocol for a randomized controlled trial
por: Meloni, Seema T., et al.
Publicado: (2019)

Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort
por: Scarsi, Kimberly K., et al.
Publicado: (2016)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study
por: De Nicolò, Amedeo, et al.
Publicado: (2022)

Low levels of HIV-1 drug resistance mutations in patients who achieved viral re-suppression without regimen switch: a retrospective study
por: Onwuamah, Chika K., et al.
Publicado: (2020)

Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week
por: Ouedraogo, Henri Gautier, et al.
Publicado: (2020)

Propofol/lopinavir/ritonavir: Bradyarrythmia: case report
Publicado: (2020)

Genotyping performance evaluation of commercially available HIV-1 drug resistance test
por: Rosemary, Audu, et al.
Publicado: (2018)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
por: Ceccaldi, Pierre-François, et al.
Publicado: (2010)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Lopinavir/ritonavir: vomiting and watery diarrhoea: case report
Publicado: (2020)

Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
Publicado: (2020)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

The administration of lopinavir/ritonavir via an enteral feeding tube()
por: Sirvent Segovia, Alejandro Esteban, et al.
Publicado: (2021)

Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings
por: Abdissa, Alemseged, et al.
Publicado: (2014)

Accumulation of Protease Mutations among Patients Failing Second-Line Antiretroviral Therapy and Response to Salvage Therapy in Nigeria
por: Rawizza, Holly E., et al.
Publicado: (2013)

Treatment Outcomes in a Decentralized Antiretroviral Therapy Program: A Comparison of Two Levels of Care in North Central Nigeria
por: Okonkwo, Prosper, et al.
Publicado: (2014)

The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients
por: Kredo, T., et al.
Publicado: (2016)

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
por: Chandwani, Ashish, et al.
Publicado: (2008)

Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2013)

Hydroxychloroquine/lopinavir/ritonavir: Exanthema and eosinophilia: 12 case reports
Publicado: (2020)

Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir
por: Mazan, Paula, et al.
Publicado: (2020)

Immunosuppressants/lopinavir/ritonavir interaction: Various toxicities: case report
Publicado: (2020)

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
por: Zhu, Zhen, et al.
Publicado: (2020)

Dexamethasone/hydroxychloroquine/lopinavir/ritonavir: Various toxicities: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o7r15gnngm689fqav5kjluls4n